Moving prevention of functional impairment upstream: is middle age an ideal time for intervention? Women’s Midlife Heal. Longitudinal benefit of positive self-perceptions of aging on functional health. Feeling old vs being old: associations between self-perceived age and mortality. Hearing loss and cognition in the Baltimore longitudinal study of aging. Association of hearing impairment and mortality in older adults. Midlife hand grip strength as a predictor of old age disability. Biomarkers of aging and falling: the beaver dam eye study. Cognitive aging and dementia: a life-span. Predicting brain-age from multimodal imaging data captures cognitive impairment. A multi-modal parcellation of human cerebral cortex. Accelerating cortical thinning: unique to dementia or universal in aging? Cereb. Longitudinal changes in individual BrainAGE in healthy aging, mild cognitive impairment, and Alzheimer’s disease. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: a systematic review and meta-analysis. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. MRI-Based biomarkers of accelerated aging and dementia risk in midlife: how close are we?. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Neurodegenerative basis of age-related cognitive decline. Quantification of biological aging in young adults. The Dunedin multidisciplinary health and development study: overview of the first 40 years, with an eye to the future. The longitudinal study of aging in human young adults: knowledge gaps and research agenda. Change in the rate of biological aging in response to caloric restriction: CALERIE Biobank. Reversal of epigenetic aging and immunosenescent trends in humans. Geroscience and the challenges of aging societies. An epigenetic biomarker of aging for lifespan and healthspan. Homeostatic dysregulation proceeds in parallel in multiple physiological systems. Eleven telomere, epigenetic clock, and biomarker-composite quantifications of biological aging: do they measure the same thing? Am. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J. Association of blood chemistry quantifications of biological aging with disability and mortality in older adults. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Healthy aging: the ultimate preventative medicine. Geroscience: linking aging to chronic disease. Aging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes. Lifespan and healthspan: past, present, and promise. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Nature Aging volume 1, pages 295–308 ( 2021) Cite this article All rights reserved.Disparities in the pace of biological aging among midlife adults of the same chronological age have implications for future frailty risk and policy In this Series paper, we discuss the use of a geriatric assessment-based approach to cancer care, and provide clinicians with tools to better assess the risks and benefits of treatment to engage in shared decision making and provide better personalised care for older people with cancer.Ĭopyright © 2018 Elsevier Ltd. The geriatric assessment is a multidimensional tool that evaluates several domains, including physical function, cognition, nutrition, comorbidities, psychological status, and social support. By contrast, a geriatric assessment can provide a much more comprehensive understanding of the functional and physiological age of an older person with cancer. Chronological age alone is often a poor indicator of the physiological and functional status of older adults, and thus should not be the main factor guiding treatment decisions in oncology. As the worldwide population ages, oncologists are often required to make difficult and complex decisions regarding the treatment of older people (aged 65 years and older) with cancer.
0 Comments
Leave a Reply. |